Literature DB >> 1349862

Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex.

S T Meller1, C Dykstra, G F Gebhart.   

Abstract

The intrathecal (i.t.) administration of either N-methyl-D-aspartate (NMDA, 10 fmol to 10 pmol) or L-arginine (1 pmol to 10 nmol), but not D-arginine (1 pmol to 10 nmol), produced a rapid, transient, dose-dependent facilitation (maximal response of 30.9 +/- 6.0% and 33.7 +/- 1.5%, respectively) of the nociceptive tail-flick reflex (ED50 = 47.8 +/- 15.4 fmol and 11.4 +/- 2.7 pmol, respectively). Maximal NMDA-produced facilitation of the tail-flick reflex (1 pmol i.t.) was completely abolished by prior treatment (10 min prior) with either N omega-nitro-L-arginine methyl ester (L-NAME, 10 nmol i.t.), methylene blue (10 nmol i.t.) or DL-5-aminophosphonovaleric acid (AP5, 100 pmol i.t.). NMDA-produced facilitation was completely recovered 40 min after L-NAME, 50 min after methylene blue and 30 min after AP5. L-NAME, methylene blue or AP5 did not significantly alter baseline tail-flick latency. These results suggest that NMDA-produced facilitation of a thermal nociceptive reflex is mediated through activation of an NMDA receptor that results in an increase in endogenous nitric oxide and activation of soluble guanylate cyclase in lumbar spinal cord.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349862     DOI: 10.1016/0014-2999(92)90102-a

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  33 in total

1.  Endothelium derived relaxing factor/nitric oxide.

Authors:  G Blaise
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

2.  Localization of nitric oxide synthase in rat trigeminal primary afferent neurons using NADPH-diaphorase histochemistry.

Authors:  I I Stoyanova; N E Lazarov
Journal:  J Mol Histol       Date:  2005-03       Impact factor: 2.611

3.  Quantitative assessment of nocifensive behavioral responses and the underlying neuronal circuitry.

Authors:  E Carstens
Journal:  Schmerz       Date:  1993-12       Impact factor: 1.107

4.  Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors.

Authors:  T Sakurada; S Katsuyama; S Sakurada; M Inoue; K Tan-No; K Kisara; C Sakurada; H Ueda; J Sasaki
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Involvement of cGMP in nociceptive processing by and sensitization of spinothalamic neurons in primates.

Authors:  Q Lin; Y B Peng; J Wu; W D Willis
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

6.  Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I.

Authors:  Irmgard Tegeder; Domenico Del Turco; Achim Schmidtko; Matthias Sausbier; Robert Feil; Franz Hofmann; Thomas Deller; Peter Ruth; Gerd Geisslinger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

7.  The dose-related effects of paracetamol on hyperalgesia and nociception in the rat.

Authors:  M Bianchi; A E Panerai
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects.

Authors:  P K Moore; P Wallace; Z Gaffen; S L Hart; R C Babbedge
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  TRPV1 and TRPA1 mediate peripheral nitric oxide-induced nociception in mice.

Authors:  Takashi Miyamoto; Adrienne E Dubin; Matt J Petrus; Ardem Patapoutian
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

10.  Involvement of S-nitrosylation of actin in inhibition of neurotransmitter release by nitric oxide.

Authors:  Jingshan Lu; Tayo Katano; Emiko Okuda-Ashitaka; Yo Oishi; Yoshihiro Urade; Seiji Ito
Journal:  Mol Pain       Date:  2009-09-29       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.